News | July 04, 2023
Biocon Biologics' Hulio Biosimilar to Humira now available in the US
The launch of HULIO in the United States is an important milestone for Biocon Biologics
The launch of HULIO in the United States is an important milestone for Biocon Biologics
The company has reported total income of Rs. 3928.8 crores during the period ended March 31, 2023
This approval reflects Biocon Biologics' compliance with the highest international regulatory standards
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
Biocon Biologics Limited will have access to 100 million doses of vaccines annually together with the distribution rights to Serum's Vaccine portfolio
For the year 2022, Biocon bettered its score in all the four EcoVadis themes – Environment (70), Labor & Human Rights (70), Ethics (60), and Sustainable Procurement (60)
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
Laurus Labs has announced that the USFDA completed inspection of the formulations manufacturing facility Unit-2, APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.
Biocon Foundation has pioneered a mHealth-technology-based (mobile health) oral cancer screening program in India
Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates
Subscribe To Our Newsletter & Stay Updated
